Assets

BPL-003

Beckley Psytech / AtaiBeckley

Molecule class

mebufotenin benzoate; described by Lilly as a synthetic form of 5-MeO-DMT, administered intranasally

Mechanism

Not independently verified. Acquirer release describes the pipeline as rapid-acting neuroplastogens designed to restore synaptic connectivity. Recorded as the company's characterisation, not ours.

Phase

Phase 2b complete; company stated Phase 3 activities initiated (Q2 2026 10-Q); no Phase 3 record on ClinicalTrials.gov or CTIS as of 2026-09-15. Sweeps 2026-09-15: intervention BPL-003 OR mebufotenin OR VLS-01 with Phase 3 filter returns 0; sponsor Beckley Psytech 7 records, max Phase 2; sponsor atai Therapeutics 3, max Phase 2; sponsor AtaiBeckley 0; sponsor Eli Lilly with those interventions 0; CTIS BPL-003 1 record (2024-513457-70-00, Ended). NCT05870540 record updated 2026-09-10, status COMPLETED unchanged

Indication

treatment-resistant depression; separate Phase 2 in alcohol use disorder

Sponsor geography

UK

Next catalyst

First Phase 3 patient dosed reported by AtaiBeckley, by 2026-09-30

Partner

Eli Lilly and Company (acquisition closed 2026-09-11)

IP status

Not checked. Recorded as unchecked rather than left blank.

The catalyst above is recorded as inferred, not verified. It is this publication's reading of the company's guidance, not a date the company has published.

clinicaltrials.govregistryverified 2026-09-15